Skip to navigation bar Skip to breadcrumbs Skip to page content
Envelope icon E-mail Updates Teal square Text size:  a A A
You are here: HomeAbout the USPSTFConflict of Interest Disclosures

Conflict of Interest Disclosures

The public must have confidence in the integrity of the process by which the U.S. Preventive Services Task Force (USPSTF or Task Force) makes its recommendations. The reputations of the USPSTF members as highly regarded researchers, clinicians, and academic scholars contribute to this objective and must be protected if the USPSTF recommendation statements are to be accepted and implemented. It is also essential that Task Force deliberations benefit from members' vigorous exchange of perspectives that are derived from and shaped by the member's research and/or practice experiences.

The intent of requesting disclosure of any potential conflict of interest is to ensure that the USPSTF provides a balanced, independent, objective, and scientifically rigorous product (including its recommendation statements) by understanding other interests that could potentially influence the work and decisionmaking of its members. The USPSTF requires each member to disclose all information regarding any possible financial and nonfinancial conflicts of interest prior to each meeting for all topics under development or that will be discussed at each meeting. Previous disclosures for continuing topics must also be updated to reflect changes in a member’s situation since the form was last completed.

Prior to each meeting or to new member appointment, all disclosures are reviewed by the Task Force Chairs according to the criteria specified in the USPSTF Procedure Manual and determined to be either Level 1, 2, or 3. The Task Force Chairs determine the final action on the member's eligibility to participate on a specific topic based on the nature and significance of the potential conflict.

  • Level 1 disclosures include nonfinancial disclosures that would not affect the judgment of a Task Force member. These disclosures do not require any action.
  • Level 2 disclosures include financial disclosures of $1,000 or less and nonfinancial disclosures that are relevant to a topic but not anticipated to affect the judgment of the Task Force member for that topic. These disclosures are announced at the Task Force meeting, but do not limit the Task Force member’s participation in the topic process.
  • Level 3 disclosures include financial disclosures of a larger amount and significant nonfinancial disclosures that may affect the Task Force member's view on the topic. Actions for Level 3 disclosures vary according to the nature of the conflict, and may include preventing the member from serving as lead of a topic or on the workgroup of a topic, preventing the member from serving as a primary spokesperson for a topic, or preventing the member from taking part in all topic activities. As all new Task Force members are reviewed for conflicts prior to joining the Task Force, Level 3 disclosures are uncommon.

All decisions are kept on file. The USPSTF Procedure Manual provides a complete description of the criteria for each level and range of possible recommended actions.

Level 3 Disclosures for Current USPSTF Members

Douglas K. Owens:

Topic: Screening for Hepatitis C Virus Infection in Adolescents and Adults

Level 3 Disclosure: Dr. Owens has extensive work experience and publications related to this topic.

Date of Disclosure: January 2017

Action: Dr. Owens may participate in the topic workgroup and deliberate and vote on this topic.

Karina W. Davidson: None

Alex H. Krist: None

Michael J. Barry: None

Michael Cabana: None

Aaron B. Caughey: 

Topic: Screening for Gestational Diabetes

Level 3 Disclosure: Dr. Caughey served as an author on the American College of Obstetricians and Gynecologists Practice Bulletin regarding the management of gestational diabetes. He has extensive research experience and multiple publications related to this topic, some of which are included in the systematic evidence review for the USPSTF

Date of Disclosure: July 2019

Action: Dr. Caughey may participate in the topic workgroup and deliberate and vote on this topic.

Chyke A. Doubeni:

Topic: Screening for Lung Cancer

Level 3 Disclosure: Dr. Doubeni has received funding from the National Cancer Institute to conduct research on lung cancer screening and prevention in community health systems, with a particular focus on optimizing uptake of guidelines and addressing health disparities in lung cancer deaths.

Date of Disclosure: January 2018

Action: Dr. Doubeni may participate in the topic workgroup and deliberate and vote on the topic.

Topic: Screening for Colorectal Cancer

Level 3 Disclosure: Dr. Doubeni has substantial experience and research expertise in this field. He has received research funding from the National Institutes of Health, served as an expert advisor on guidelines and other panels, and authored multiple publications related to this topic.

Date of Disclosure: March 2019

Action: Dr. Doubeni may participate in the topic workgroup and deliberate and vote on the topic.

John W. Epling, Jr.: None

Martha Kubik: None

C. Seth Landefeld: None

Carol M. Mangione: None

Lori Pbert:

Topic: Interventions to Prevent Tobacco and Nicotine Use in Children and Adolescents

Level 3 Disclosure: Dr. Pbert has substantial experience and research expertise in this field. She has received research funding from the National Institutes of Health and authored multiple publications related to this topic.

Date of Disclosure: March 2019

Action: Dr. Pbert may participate in the topic workgroup and deliberate and vote on the topic.

Topic: Interventions for Tobacco Cessation in Adults, Including Pregnant Women

Level 3 Disclosure: Dr. Pbert is the director of the Center for Tobacco Treatment Research and Training at the University of Massachusetts Medical School, which has a contract with the Massachusetts Department of Public Health to provide training and technical assistance to state efforts to reduce tobacco use.

Date of Disclosure: March 2019

Action: Dr. Pbert may participate in the topic workgroup and deliberate and vote on the topic.

Michael Silverstein: None

Melissa A. Simon:

Topic: Medication Use to Reduce Risk of Breast Cancer

Level 3 Disclosure: Dr. Simon has received a grant from the Pfizer Foundation. Pfizer Inc. is the maker of AROMASIN® (an aromatase inhibitor) and tamoxifen citrate tablets. Tamoxifen is the primary medication that is being considered for this topic, and aromatase inhibitors may also be considered. This has been determined to be a topic where there is a possible direct conflict.

Date of Disclosure: January 2017

Action: Dr. Simon will be recused from the topic. She may not participate in the topic workgroup or deliberate or vote on the topic.

Topic: Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer

Level 3 Disclosure: Dr. Simon has received a grant from the Pfizer Foundation.

Date of Disclosure: January 2017

Action: Dr. Simon may participate in the topic workgroup and deliberate and vote on the topic.

Topic: Screening for Gestational Diabetes

Level 3 Disclosure: Dr. Simon has publications related to this topic, one of which is included in the systematic evidence review for the USPSTF.

Date of Disclosure: July 2019

Action: Dr. Simon may participate in the topic workgroup and deliberate and vote on the topic.

Chien-Wen Tseng: None

John B. Wong:

Topic: Screening for Lung Cancer

Level 3 Disclosure: Dr. Wong has authored multiple publications related to lung cancer and has received funding from the National Institutes of Health to develop a policy simulation model to estimate health and economic outcomes of screening for lung cancer.

Date of Disclosure: February 2018

Action: Dr. Wong may participate in the topic workgroup and deliberate and vote on the topic.

Topics: Screening for Hepatitis C Virus Infection in Adolescents and Adults

Level 3 Disclosure: Dr. Wong has conducted research, worked on guidelines, and authored publications related to these topics.

Date of Disclosure: February 2018

Action: Dr. Wong may participate in the topic workgroups and deliberate and vote on the topics.

Current as of: August 2019

Internet Citation: Conflict of Interest Disclosures. U.S. Preventive Services Task Force. August 2019.
https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857